))
Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
1
Episode 316: APCCC 2024 Summary with Silke Gillessen
41:11
41:11
Play later
Play later
Lists
Like
Liked
41:11
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
…
continue reading
1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
18:17
18:17
Play later
Play later
Lists
Like
Liked
18:17
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
…
continue reading
1
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
25:15
25:15
Play later
Play later
Lists
Like
Liked
25:15
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
…
continue reading
1
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
35:40
35:40
Play later
Play later
Lists
Like
Liked
35:40
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
…
continue reading
1
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
23:56
23:56
Play later
Play later
Lists
Like
Liked
23:56
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
…
continue reading
1
Episode 311: The Uromigos Paper of the Month - The POUT Trial
36:02
36:02
Play later
Play later
Lists
Like
Liked
36:02
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
…
continue reading
1
Episode 310: Dosing and duration of drugs from a cost perspective
28:28
28:28
Play later
Play later
Lists
Like
Liked
28:28
Daniel Goldstein describes his work on this issue.
…
continue reading
1
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
27:13
27:13
Play later
Play later
Lists
Like
Liked
27:13
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
…
continue reading
1
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
23:09
23:09
Play later
Play later
Lists
Like
Liked
23:09
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
…
continue reading
1
Episode 307: Bladder-Sparing Approaches Part 2
35:14
35:14
Play later
Play later
Lists
Like
Liked
35:14
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
…
continue reading
1
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
29:56
29:56
Play later
Play later
Lists
Like
Liked
29:56
Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
…
continue reading
1
Episode 305: FDA and Oncology Clinical Trials
29:35
29:35
Play later
Play later
Lists
Like
Liked
29:35
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
…
continue reading
1
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
30:43
30:43
Play later
Play later
Lists
Like
Liked
30:43
Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
…
continue reading
Michael Lattanzi discusses treatment plans and research in the community.
…
continue reading
1
Episode 302: Part 2- Adjuvant Therapy in solid tumors
34:37
34:37
Play later
Play later
Lists
Like
Liked
34:37
Hans Hammers discusses trial design and patient selection in the adjuvant setting.
…
continue reading
1
Episode 301: Cancer research from a global perspective.
31:06
31:06
Play later
Play later
Lists
Like
Liked
31:06
Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries
…
continue reading
1
Episode 300: Adjuvant PD1 Therapy in Solid Tumours
42:15
42:15
Play later
Play later
Lists
Like
Liked
42:15
David McDermott discusses melanoma and renal data. We never get to bladder or lung.
…
continue reading
1
Episode 299: Androgen receptor ligand-directed degrader BMS-986365
36:40
36:40
Play later
Play later
Lists
Like
Liked
36:40
Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer
…
continue reading
Silke, Tom and Brian cover the bases.
…
continue reading
1
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath
22:46
22:46
Play later
Play later
Lists
Like
Liked
22:46
Neeraj Agarwal addresses the issues raised at the meeting.
…
continue reading
1
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
23:58
23:58
Play later
Play later
Lists
Like
Liked
23:58
Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005
…
continue reading
1
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
32:46
32:46
Play later
Play later
Lists
Like
Liked
32:46
Pedro Barata summarises his ASCO GU discussion on this topic.
…
continue reading
1
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
33:17
33:17
Play later
Play later
Lists
Like
Liked
33:17
Andrea Apolo describes the results of this positive trial.
…
continue reading
1
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
22:21
22:21
Play later
Play later
Lists
Like
Liked
22:21
Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.
…
continue reading
1
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
26:04
26:04
Play later
Play later
Lists
Like
Liked
26:04
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
…
continue reading
1
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
31:15
31:15
Play later
Play later
Lists
Like
Liked
31:15
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
…
continue reading
What to look out for in bladder, prostate and renal cancer at this year's meeting.
…
continue reading
1
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
36:02
36:02
Play later
Play later
Lists
Like
Liked
36:02
Karim Fizazi discusses the clinical and biomarker components of this data.
…
continue reading
1
Episode 288: APCCC #3: Controversies around Radiotherapy
36:29
36:29
Play later
Play later
Lists
Like
Liked
36:29
Thomas Zilli discusses controversies around radiotherapy in prostate cancer.
…
continue reading
1
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
34:48
34:48
Play later
Play later
Lists
Like
Liked
34:48
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
…
continue reading
1
Episode 286: APCCC Prostate Cancer Meeting Overview
30:22
30:22
Play later
Play later
Lists
Like
Liked
30:22
Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.
…
continue reading
1
Episode 285: Holiday Special: Renal Cancer in 2023
26:02
26:02
Play later
Play later
Lists
Like
Liked
26:02
Cristina Suarez discusses the year in review.
…
continue reading
1
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
37:56
37:56
Play later
Play later
Lists
Like
Liked
37:56
Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023
…
continue reading
1
Episode 283: Holiday Special: Prostate Cancer in 2023
34:34
34:34
Play later
Play later
Lists
Like
Liked
34:34
Tanya Dorff discusses her favourite prostate cancer studies of the year.
…
continue reading
1
Episode 282: Holiday Special: Bladder Cancer in 2023
38:12
38:12
Play later
Play later
Lists
Like
Liked
38:12
Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.
…
continue reading
1
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
25:23
25:23
Play later
Play later
Lists
Like
Liked
25:23
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.
…
continue reading
Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.
…
continue reading
Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.
…
continue reading
1
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
1:00:37
1:00:37
Play later
Play later
Lists
Like
Liked
1:00:37
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
…
continue reading
1
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
39:31
39:31
Play later
Play later
Lists
Like
Liked
39:31
Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.…
…
continue reading
1
Episode 277: NMIBC Discussion at #UromigosLive 2023
44:04
44:04
Play later
Play later
Lists
Like
Liked
44:04
Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.…
…
continue reading
Silke Gillessen joins Tom and Brian to give a summary of the meeting,
…
continue reading
1
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
13:30
13:30
Play later
Play later
Lists
Like
Liked
13:30
Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.
…
continue reading
1
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
19:46
19:46
Play later
Play later
Lists
Like
Liked
19:46
Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.
…
continue reading
1
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
13:47
13:47
Play later
Play later
Lists
Like
Liked
13:47
Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng
…
continue reading
1
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
31:32
31:32
Play later
Play later
Lists
Like
Liked
31:32
Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)
…
continue reading
1
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
23:30
23:30
Play later
Play later
Lists
Like
Liked
23:30
Yohann Loriot described the 2 Thor randomised phase 3 studies
…
continue reading
1
Episode 270: ESMO 2023 - Belzutifan in renal cancer
28:26
28:26
Play later
Play later
Lists
Like
Liked
28:26
Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer
…
continue reading
1
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC
24:52
24:52
Play later
Play later
Lists
Like
Liked
24:52
Brad McGregor discuses the DAD trial exploring this combo for the 1st time
…
continue reading
1
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
27:06
27:06
Play later
Play later
Lists
Like
Liked
27:06
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
…
continue reading
